This tiered approach allows investors to engage at the level they’re most comfortable with, sparking their interest with a ...

The team from the University of Bath in the UK, Poland's Kozminski Academy and Lund University in Sweden have concluded that ...

The UK's Poolbeg Pharma has disclosed that it is in talks over a possible takeover by Hookipa, an Austrian biotech that is listed on the Nasdaq.

CARsgen Therapeutics' claudin 18.2-targeting autologous CAR-T therapy satricabtagene autoleucel (satri-cel) has shown efficacy in gastric cancer, in a rare win for this type of cell therapy in a solid ...

Regeneron has bought Oxular, a UK-based specialist in retinal diseases, in a move that bolsters its already strong position ...

Although Boston, San Francisco, and San Diego are the top three life sciences markets in the US, they are burdened by an oversupply of lab buildings that offer lab space. There is an undersupply of ...

Capricor Therapeutics has completed its US marketing application for deramiocel, a cell therapy the US biotech hopes will ...

Pfizer has partnered with a ‘computation-driven’ pharmaceutical technology company to develop a drug discovery platform powered by artificial intelligence (AI). Its collaboration with ...

Biogen says it is the first drugmaker in the US to get FDA approval for a biosimilar of Roche’s $3 billion blockbuster product Actemra. The intravenous biosimilar of IL-6 inhibitor Actemra ...

In a statement, Neumora revealed that the KOASTAL-1 study missed its primary endpoint, with navacaprant failing to achieve a ...

The JV was set up in 2001 and has become increasingly peripheral to Hutchmed's core business of developing novel therapies ...